New Indications of mTOR Inhibitors in Rare Tumors

The last decade has witnessed a rapid advancement in our understanding of the complexity of the mechanistic target of rapamycin (mTOR) pathway. Growing evidence linking hyperactivated mTOR signaling to cancer has piqued an interest in targeting this pathway in the development of anticancer therapies. mTOR inhibitors have shown clear benefit in rare cancers and tumors, such as tuberous sclerosis complex (TSC)-associated tumors, renal cell carcinoma (RCC), and neuroendocrine tumors.